Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Multiomics analysis of tumor mutational burden across cancer types. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa1504627
10.1056/nejmoa1504627 · External reference
10.1038/nature13904
10.1038/nature13904 · External reference
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
10.1016/s0140-6736(14)60958-2 · 2014 · External reference
10.1016/j.cell.2016.08.069
10.1016/j.cell.2016.08.069 · External reference
Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
10.1016/j.eururo.2018.03.015 · 2018 · External reference
10.1126/scitranslmed.aad7118
10.1126/scitranslmed.aad7118 · External reference
10.1093/annonc/mdy495
10.1093/annonc/mdy495 · External reference
Methods of measurement for tumor mutational burden in tumor tissue
10.21037/tlcr.2018.08.02 · 2018 · External reference
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
10.1186/s40425-019-0647-4 · 2019 · External reference
10.1126/science.aaa1348
10.1126/science.aaa1348 · External reference
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
10.1126/science.aad0095 · 2015 · External reference
10.1056/nejmoa1801946
10.1056/nejmoa1801946 · External reference
10.1038/s41588-018-0312-8
10.1038/s41588-018-0312-8 · External reference
10.1158/1535-7163.mct-17-0386
10.1158/1535-7163.mct-17-0386 · External reference
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations
10.1371/journal.pone.0080023 · 2013 · External reference
10.1200/jco.18.01798
10.1200/jco.18.01798 · External reference
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
10.1073/pnas.1607836113 · 2016 · External reference
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer
10.3389/fcell.2020.608969 · 2020 · External reference
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients
10.1186/s40478-015-0265-4 · 2015 · External reference
Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis
2020 · External reference
10.18632/aging.104204
10.18632/aging.104204 · External reference
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
10.1186/s13073-017-0424-2 · 2017 · External reference
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
10.1002/ijc.32002 · 2019 · External reference
10.1016/j.annonc.2021.02.006
10.1016/j.annonc.2021.02.006 · External reference
10.1073/pnas.0506580102
10.1073/pnas.0506580102 · External reference
10.1038/ng1180
10.1038/ng1180 · External reference
10.1093/nar/gkaa407
10.1093/nar/gkaa407 · External reference
10.1158/1538-7445.am2017-108
10.1158/1538-7445.am2017-108 · External reference
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
2016 · External reference
10.1002/advs.201902880
10.1002/advs.201902880 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1093/nar/gkv1507
10.1093/nar/gkv1507 · External reference
10.1038/nature08250
10.1038/nature08250 · External reference
10.1016/j.ccell.2016.04.001
10.1016/j.ccell.2016.04.001 · External reference
10.1038/s41568-020-0290-x
10.1038/s41568-020-0290-x · External reference
10.1038/nature12213
10.1038/nature12213 · External reference
10.1016/j.mad.2008.02.012
10.1016/j.mad.2008.02.012 · External reference
Comprehensive mismatch repair gene panel identifies variants in patients with Lynch-like syndrome
10.1002/mgg3.850 · 2019 · External reference
Conserved domains in DNA repair proteins and evolution of repair systems
10.1093/nar/27.5.1223 · 1999 · External reference
Unresolved reference
External reference
10.1038/nrm1907
10.1038/nrm1907 · External reference
10.1038/cr.2007.115
10.1038/cr.2007.115 · External reference
10.1002/jcp.10077
10.1002/jcp.10077 · External reference
10.1038/ng.298
10.1038/ng.298 · External reference
10.1016/j.molcel.2008.05.007
10.1016/j.molcel.2008.05.007 · External reference
10.1038/nmeth.3337
10.1038/nmeth.3337 · External reference
10.1002/mgg3.787
10.1002/mgg3.787 · External reference
Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles
2020 · External reference
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
2019 · External reference
10.1089/omi.2011.0118
10.1089/omi.2011.0118 · External reference
10.21037/atm.2019.10.116
10.21037/atm.2019.10.116 · External reference
Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
10.3389/fonc.2020.573141 · 2020 · External reference
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
2019 · External reference
Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer
2020 · External reference
10.1093/annonc/mdz197
10.1093/annonc/mdz197 · External reference
Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma
2021 · External reference
10.1016/j.intimp.2020.107126
10.1016/j.intimp.2020.107126 · External reference
Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications
2019 · External reference
Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma
2020 · External reference
Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
10.1038/bjc.2012.524 · 2013 · External reference
10.1016/j.csbj.2019.07.009 · Admitted local publication
Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer
2021 · External reference
10.18632/aging.202756
10.18632/aging.202756 · External reference
An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma
10.3389/fonc.2020.00853 · 2020 · External reference
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
10.7150/jca.48983 · 2021 · External reference
10.1016/j.immuni.2013.10.003
10.1016/j.immuni.2013.10.003 · External reference
10.1016/j.ejca.2008.05.017
10.1016/j.ejca.2008.05.017 · External reference
Prognostic significance of the infiltration of CD163(+) macrophages combined with CD66b(+) neutrophils in gastric cancer
10.1002/cam4.1420 · 2018 · External reference
